EUVIMEDObjevte EUVIMED
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen access · CC BY-NC 4.0

Weight reduction over time in tirzepatide‐treated participants by early weight loss response: Post hoc analysis in SURMOUNT‐1

Jamy Ard iD, Clare J Lee, Kimberly Gudzune, Brandi Addison, Ildiko Lingvay iD, Dachuang Cao, Casey J Mast iD, Adam Stefanski, Beverly Falcon, Donna Mojdami

Diabetes, Obesity and Metabolism · 2025-09 · 27 (9) · 5064-5071

DOI: 10.1111/dom.16554 ↗

At a glance

Klinische Studie (Phase III) in Diabetes, Obesity and Metabolism, published online on 2025-07-17. Written by Jamy Ard and 9 co-authors. Institution: Departments of Epidemiology & Prevention and Internal Medicine Vice Dean for Clinical Research, Wake Forest University School of Medicine, Winston-Sa…. Major MEDLINE topics: Anti-Obesity Agents, Diabetes Mellitus, Type 2, Obesity, Weight Loss. Cited 19 times so far (Crossref); 28 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Eli Lilly and Company.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Aims The objective was to assess weight reduction at Weeks 24 and 72 in participants treated with tirzepatide based on weight reduction response after 12 weeks of treatment in the SURMOUNT‐1 trial. Materials and Methods This post hoc analysis included participants treated with tirzepatide who received ≥75% of the assigned treatment doses and had weight measurements at Weeks 0, 12, 24 and 72. Participants were categorized based on the 12‐week response to tirzepatide: late responders (

Subjects

MeSH terms (MEDLINE)

Anti-Obesity AgentsDiabetes Mellitus, Type 2ObesityWeight LossGlucagon-Like Peptide-1 Receptor AgonistsAdultAgedFemaleHumansMaleMiddle AgedBody Mass IndexTime FactorsTirzepatideTreatment OutcomeWaist Circumference

Author keywords

responsetirzepatide

Substances

Anti-Obesity AgentsTirzepatideGlucagon-Like Peptide-1 Receptor Agonists

Authors and institutions

  • Departments of Epidemiology & Prevention and Internal Medicine Vice Dean for Clinical Research, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
  • Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • South Texas Endocrinology & Metabolism Center, PLLC, Corpus Christi, Texas, USA.
  • UT Southwestern Medical Center, Dallas, Texas, USA.

ORCID profiles: Jamy Ard, Ildiko Lingvay, Casey J Mast

Funding

  • Eli Lilly and Company

Cite

APA

Ard, J., Lee, C. J., Gudzune, K., Addison, B., Lingvay, I., Cao, D., Mast, C. J., Stefanski, A., Falcon, B., & Mojdami, D. (2025). Weight reduction over time in tirzepatide‐treated participants by early weight loss response: Post hoc analysis in SURMOUNT‐1. Diabetes, Obesity and Metabolism, 27(9), 5064-5071. https://doi.org/10.1111/dom.16554

Vancouver

Ard J, Lee CJ, Gudzune K, Addison B, Lingvay I, Cao D, et al. Weight reduction over time in tirzepatide‐treated participants by early weight loss response: Post hoc analysis in SURMOUNT‐1. Diabetes, Obesity and Metabolism. 2025;27(9):5064-5071. doi:10.1111/dom.16554

BibTeX
@article{Ard2025,
  author = {Ard, Jamy and Lee, Clare J and Gudzune, Kimberly and Addison, Brandi and Lingvay, Ildiko and Cao, Dachuang and Mast, Casey J and Stefanski, Adam and Falcon, Beverly and Mojdami, Donna},
  title = {Weight reduction over time in tirzepatide‐treated participants by early weight loss response: Post hoc analysis in SURMOUNT‐1},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  volume = {27},
  number = {9},
  pages = {5064--5071},
  doi = {10.1111/dom.16554}
}
Start for free →